1Day Sooner — General Support (2021)

Open Philanthropy recommended a grant of $2,000,000 to 1Day Sooner for general support. 1Day Sooner’s mission is to advocate on behalf of volunteers for human challenge trials (HCTs). They hope to accelerate the development of vaccines for several neglected diseases by organizing volunteers to take part in HCTs, and by advocating for the use of regulatory and financial tools like advance market commitments.

HCTs, which involve exposing volunteers to a controlled dose of a pathogen, require fewer participants and can be completed on a significantly shorter timeline than standard clinical trials. They have historically been used for smallpox, influenza, malaria, and other potentially fatal diseases.

This follows our November 2020 support and falls within our focus area of biosecurity and pandemic preparedness.

1Day Sooner — General Support (November 2020)


Grant Investigator: Holden Karnofsky

This page was reviewed but not written by the grant investigator. 1Day Sooner staff also reviewed this page prior to publication.


Open Philanthropy recommended a grant of $600,000 to 1Day Sooner for general support. 1Day Sooner’s mission is to advocate on behalf of volunteers for COVID-19 human challenge trials (HCTs). They hope to accelerate the development and deployment of a vaccine for COVID-19 by raising awareness about, organizing volunteers around, and otherwise laying the groundwork for HCTs.

HCTs, which involve exposing volunteers to a controlled dose of a pathogen, require fewer participants and can be completed on a significantly shorter timeline than standard randomized control trials, and have been historically used for smallpox, influenza, malaria, and other potentially fatal diseases. The idea of and preconditions for employing HCTs to accelerate a COVID-19 vaccine were discussed by Harvard epidemiologist Marc Lipsitch, London School of Hygiene and Tropical Medicine epidemiologist Peter Smith, and Rutgers bioethicist Nir Eyal in a paper published in The Journal of Infectious Diseases earlier this year.

This follows our May 2020 support and falls within our focus area of biosecurity and pandemic preparedness.

Sources

Document Source
Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure, The Journal of Infectious Diseases, 2020 Source

1Day Sooner — General Support (May 2020)


Grant Investigator: Holden Karnofsky

This page was reviewed but not written by the grant investigator. 1Day Sooner staff also reviewed this page prior to publication.


Open Philanthropy recommended a grant of $500,000 to 1Day Sooner, via WaitList Zero, for general support. 1Day Sooner’s mission is to advocate on behalf of volunteers for COVID-19 human challenge trials (HCTs). They hope to accelerate the development and deployment of a vaccine for COVID-19 by raising awareness about, organizing volunteers around, and otherwise laying the groundwork for HCTs.

HCTs, which involve exposing volunteers to a controlled dose of a pathogen, require fewer participants and can be completed on a significantly shorter timeline than standard randomized control trials, and have been historically used for smallpox, influenza, malaria, and other potentially fatal diseases. The idea of and preconditions for employing HCTs to accelerate a COVID-19 vaccine were discussed by Harvard epidemiologist Marc Lipsitch, London School of Hygiene and Tropical Medicine epidemiologist Peter Smith, and Rutgers bioethicist Nir Eyal in a paper published in The Journal of Infectious Diseases earlier this year.

This falls within our focus area of biosecurity and pandemic preparedness.

Sources

Document Source
Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure, The Journal of Infectious Diseases, 2020 Source